Search company, investor...


Series A | Alive

Total Raised


Last Raised

$5.6M | 14 yrs ago

About PDC Biotech

PDC Biotech is developing a compound, PDC31 which is being developed for the treatment of preterm labor and primary dysmenorrhea. PDC31 is a peptide antagonist of the prostaglandin F2a (FP) receptor, the lead in a series of FP antagonists exclusively licensed to PDC Biotech GmbH from Theratechnologies, (TSX: TH), a Canadian biopharmaceutical company.

Headquarters Location




PDC Biotech Frequently Asked Questions (FAQ)

  • What is PDC Biotech's latest funding round?

    PDC Biotech's latest funding round is Series A.

  • How much did PDC Biotech raise?

    PDC Biotech raised a total of $5.6M.

  • Who are the investors of PDC Biotech?

    Investors of PDC Biotech include MIG Verwaltungs and Andera Partners.

  • Who are PDC Biotech's competitors?

    Competitors of PDC Biotech include Zogenix, Asteres, Intarcia Therapeutics, Altor BioScience, Anacor Pharmaceuticals and 7 more.


Compare PDC Biotech to Competitors

Intarcia Therapeutics

Intarcia Therapeutics operates as a biopharmaceutical company. The company develops and commercializes therapies to transform the prevention and management of chronic diseases. The company was founded in 1995 and is based in Boston, Massachusetts.


Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and well-being in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.


Osteologix develops pharmaceutical products for bone and cartilage disorders addressing large markets and offering low-risk development. The therapies developed by Osteologix represent valuable solutions to the patients suffering from diseases of bone and cartilage, and they represent cost-effective therapeutic options for the healthcare providers. Osteologix's lead compound for prophylaxis and treatment of osteoporosis is being developed for multiple clinical indications. The main program is aimed at osteoporosis. Additional programs are aimed at secondary indications in metabolic bone diseases and OA exploiting maximal synergies with the Osteoporosis program.

Intercept Pharmaceuticals

Intercept Pharmaceuticals engages in the development and commercialization of novel therapeutics in the healthcare sector. Its offerings include the development and delivery of medicines for conditions such as primary biliary cholangitis and severe alcohol-associated hepatitis. The company primarily serves the healthcare industry, with a particular emphasis on liver health. It was founded in 2002 and is based in Morristown, New Jersey.

NeuroMolecular Pharmaceuticals

NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.


ThyroChek is the only available rapid test for elevated TSH approved by the FDA. It is a rapid, qualitative test for elevated TSH, thyroid stimulating hormone, a clinical indicator of hypothyroidism. Screening Devices Canada is producing products for the thyroid health market in the United States which is a market valued at $1.2B annually.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.